Tuğba Yanık Yalçın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tuğba Yanık Yalçın has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Ozlem Kurt-Azap
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Başkent University, Ankara, Türkiye
13 shared publications - Nuran Sarı
Department of Infectious Diseases and Clinical Microbiology, Başkent University Faculty of Medicine, Ankara, Türkiye
8 shared publications - Hande Arslan
Department of Infectious Diseases and Clinical Microbiology Baskent University Faculty of Medicine Ankara Türkiye
7 shared publications - Çiğdem Erol
Department of Infectious Diseases and Clinical Microbiology, Baskent University School of Medicine, Ankara, Turkey
7 shared publications - Fatma İrem Yeşiler
Department of Anesthesiology and Critical Care Unit, Faculty of Medicine, Başkent University, Ankara, Türkiye
5 shared publications - Helin Şahintürk
Department of Anesthesiology and Critical Care Unit, Faculty of Medicine, Başkent University, Ankara, Türkiye
5 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Turkish Society of Intensive Care in Turkish Journal of Intensive Care
- Vol. 24 (3) , 165-172
Antimicrobial stewardship practices in the intensive care unit: a pre–post interventional study
Objective: This study aims to assess the frequency of drug-related problems (DRPs) related to antimicrobial drugs in the ICU and to examine changes in the use of antibiotics in the ‘Reserve’ group of the World Health Organization (WHO) AWaRe classification during the antimicrobial stewardship (AMS) team intervention, including the clinical pharmacist. Methods: In this single-center intervention study, the pre-intervention period between November 2021 and August 2022 and the post-intervention period between November 2022 and August 2023 were evaluated. In the post-intervention period, a clinical pharmacist was also included in the AMS team. Post-intervention medication-related problems (DRPs) were categorized using only the “problem” and “cause” domains of the Pharmaceutical Care Network Europe (PCNE) V9.1 classification system. Additionally, recommendations and their acceptance rates were recorded. The antibiotic use density of the ‘Reserve’ group, defined in the WHO AWaRe classification, was evaluated in terms of days of therapy (DOT) per 1000 patient-days. Results: After the intervention, 175 DRPs were detected in 67.1% of 173 patients; 70% were related to antimicrobial drugs. The 90.1% of the interventions suggested by the clinical pharmacist were evaluated and accepted by infectious diseases and intensive care specialists. The total use of “Reserve” group antibiotics decreased, but not significantly; significant decreases were observed for some agents such as linezolid and daptomycin. Conclusion: Multidisciplinary antimicrobial stewardship practices involving the clinical pharmacist can contribute to the prevention of antimicrobial resistance development by facilitating the detection and solution of DRPs, especially by reducing the use of ‘Reserve’ group antimicrobials.
- 24 September 2026
- Published by Turkish Society of Intensive Care in Turkish Journal of Intensive Care
- Vol. 24 (3) , 165-172
Open AccessAntimicrobial stewardship practices in the intensive care unit: a pre–post interventional study
Objective: This study aims to assess the frequency of drug-related problems (DRPs) related to antimicrobial drugs in the ICU and to examine changes in the use of antibiotics in the ‘Reserve’ group of the World Health Organization (WHO) AWaRe classification during the antimicrobial stewardship (AMS) team intervention, including the clinical pharmacist. Methods: In this single-center intervention study, the pre-intervention period between November 2021 and August 2022 and the post-intervention period between November 2022 and August 2023 were evaluated. In the post-intervention period, a clinical pharmacist was also included in the AMS team. Post-intervention medication-related problems (DRPs) were categorized using only the “problem” and “cause” domains of the Pharmaceutical Care Network Europe (PCNE) V9.1 classification system. Additionally, recommendations and their acceptance rates were recorded. The antibiotic use density of the ‘Reserve’ group, defined in the WHO AWaRe classification, was evaluated in terms of days of therapy (DOT) per 1000 patient-days. Results: After the intervention, 175 DRPs were detected in 67.1% of 173 patients; 70% were related to antimicrobial drugs. The 90.1% of the interventions suggested by the clinical pharmacist were evaluated and accepted by infectious diseases and intensive care specialists. The total use of “Reserve” group antibiotics decreased, but not significantly; significant decreases were observed for some agents such as linezolid and daptomycin. Conclusion: Multidisciplinary antimicrobial stewardship practices involving the clinical pharmacist can contribute to the prevention of antimicrobial resistance development by facilitating the detection and solution of DRPs, especially by reducing the use of ‘Reserve’ group antimicrobials.
- Open Access
- 28 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- p. 330
Infection Prevention and Control in Türkiye: A Consensus Report from the 7th National Healthcare-Associated Infections Symposium
Antimicrobial resistance continues to threaten modern healthcare systems, increasing the importance of effective infection prevention and control (IPC). This study presents a thematic analysis of discussions from the 7th National Healthcare-Associated Infections Symposium (Ulusal Sağlık Bakımıyla İlişkili İnfeksiyonlar Simpozyumu, USBİS). Audio-recorded sessions involving IPC leaders and healthcare professionals across Türkiye were transcribed and analyzed to identify persistent barriers and potential solutions. Key barriers included reporting pressures affecting data reliability, behavioral and cultural barriers, limitations in education and workforce capacity, gaps in standardization, and difficulties implementing infection control committee decisions. Participants emphasized strengthening institutional IPC culture, improving leadership visibility, simplifying data systems, and prioritizing sustainable behavioral change strategies.
- 28 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- p. 330
Open AccessInfection Prevention and Control in Türkiye: A Consensus Report from the 7th National Healthcare-Associated Infections Symposium
Antimicrobial resistance continues to threaten modern healthcare systems, increasing the importance of effective infection prevention and control (IPC). This study presents a thematic analysis of discussions from the 7th National Healthcare-Associated Infections Symposium (Ulusal Sağlık Bakımıyla İlişkili İnfeksiyonlar Simpozyumu, USBİS). Audio-recorded sessions involving IPC leaders and healthcare professionals across Türkiye were transcribed and analyzed to identify persistent barriers and potential solutions. Key barriers included reporting pressures affecting data reliability, behavioral and cultural barriers, limitations in education and workforce capacity, gaps in standardization, and difficulties implementing infection control committee decisions. Participants emphasized strengthening institutional IPC culture, improving leadership visibility, simplifying data systems, and prioritizing sustainable behavioral change strategies.
- Open Access
- 1 October 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (10) , e0023825
Exploring determinants in deciding the optimal antimicrobial dose in patients undergoing CRRT: a mixed-methods study
Antimicrobial dosing in patients undergoing continuous renal replacement therapy (CRRT) is a clinical challenge. The study aimed to investigate the factors that influence appropriate antimicrobial doses in CRRT and to address gaps in current knowledge and practice. The mixed-method design involved two phases. For the quantitative phase, infectious disease, intensive care, and clinical pharmacy professionals completed a questionnaire assessing demographics and practice details, as well as their knowledge, attitudes, and practices on antibiotic dosing in CRRT. In the qualitative phase, online focus groups were conducted using a question schedule based on the Theoretical Domains Framework to explore challenges and expectations. A structured questionnaire was completed by 160 participants, most of whom were infectious disease specialists (61.3%) with over 10 years of experience (38.8%). Despite a high knowledge level of antimicrobial dosing during CRRT, the sieving coefficient was unclear at 74.4%. Although 96.3% reported adjusting doses, 78.8% lacked institutional guidelines, and 68.1% did not monitor drug levels. CRRT experience positively influenced knowledge and attitude scores, and different dosing practices were reported for meropenem, piperacillin-tazobactam, and vancomycin. Qualitative findings highlighted the need for standard guidelines and CRRT-specific training. Multidisciplinary collaboration and real-time monitoring of therapeutic drugs were emphasized. This study identifies key gaps in knowledge and practice regarding antimicrobial dosing in CRRT. Addressing these gaps requires targeted training programs, real-time drug monitoring, and the development of evidence-based dosing guidelines to enhance patient safety and antimicrobial efficacy. Future research should evaluate the impact of these interventions on clinical outcomes.
- 1 October 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (10) , e0023825
Open AccessExploring determinants in deciding the optimal antimicrobial dose in patients undergoing CRRT: a mixed-methods study
Antimicrobial dosing in patients undergoing continuous renal replacement therapy (CRRT) is a clinical challenge. The study aimed to investigate the factors that influence appropriate antimicrobial doses in CRRT and to address gaps in current knowledge and practice. The mixed-method design involved two phases. For the quantitative phase, infectious disease, intensive care, and clinical pharmacy professionals completed a questionnaire assessing demographics and practice details, as well as their knowledge, attitudes, and practices on antibiotic dosing in CRRT. In the qualitative phase, online focus groups were conducted using a question schedule based on the Theoretical Domains Framework to explore challenges and expectations. A structured questionnaire was completed by 160 participants, most of whom were infectious disease specialists (61.3%) with over 10 years of experience (38.8%). Despite a high knowledge level of antimicrobial dosing during CRRT, the sieving coefficient was unclear at 74.4%. Although 96.3% reported adjusting doses, 78.8% lacked institutional guidelines, and 68.1% did not monitor drug levels. CRRT experience positively influenced knowledge and attitude scores, and different dosing practices were reported for meropenem, piperacillin-tazobactam, and vancomycin. Qualitative findings highlighted the need for standard guidelines and CRRT-specific training. Multidisciplinary collaboration and real-time monitoring of therapeutic drugs were emphasized. This study identifies key gaps in knowledge and practice regarding antimicrobial dosing in CRRT. Addressing these gaps requires targeted training programs, real-time drug monitoring, and the development of evidence-based dosing guidelines to enhance patient safety and antimicrobial efficacy. Future research should evaluate the impact of these interventions on clinical outcomes.
- Open Access
- 25 September 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (3) , 273-282
Impact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye
Healthcare-associated infections (HAIs) are common yet largely preventable through adherence to evidence-based guidelines. In 2005, Türkiye implemented a national infection control program, which led to significant reductions in HAI rates, including a 50% decrease in central line-associated bloodstream infections (CLABSIs) between 2008 and 2017. This result was in parallel with data from
- 25 September 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (3) , 273-282
Open AccessImpact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye
Healthcare-associated infections (HAIs) are common yet largely preventable through adherence to evidence-based guidelines. In 2005, Türkiye implemented a national infection control program, which led to significant reductions in HAI rates, including a 50% decrease in central line-associated bloodstream infections (CLABSIs) between 2008 and 2017. This result was in parallel with data from
- Open Access
- 19 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 6 (4) , 328-333
Intraventricular Tigecycline Therapy for Ventriculoperitoneal Shunt-Related Septic Shock Caused by Colistin-Resistant Klebsiella pneumoniae: A Case Report
Ventriculoperitoneal shunts (VPSs) have been shown to be effective life-saving treatments for hydrocephalus. Nonetheless, the occurrence of VPS-related complications and infections necessitates close monitoring and care. Due to blood-brain and blood-cerebrospinal fluid (CSF) barriers, many anti-infective therapeutics have difficulty […]
- 19 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 6 (4) , 328-333
Open AccessIntraventricular Tigecycline Therapy for Ventriculoperitoneal Shunt-Related Septic Shock Caused by Colistin-Resistant Klebsiella pneumoniae: A Case Report
Ventriculoperitoneal shunts (VPSs) have been shown to be effective life-saving treatments for hydrocephalus. Nonetheless, the occurrence of VPS-related complications and infections necessitates close monitoring and care. Due to blood-brain and blood-cerebrospinal fluid (CSF) barriers, many anti-infective therapeutics have difficulty […]
- Open Access
- 19 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 6 (4) , 320-327
Isolation and Antibiotic Resistance Rates of Mycobacterium tuberculosis complex in Mycolor TK® System
Tuberculosis (TB) is a common disease with high mortality and morbidity worldwide. Globally, an estimated 10.6 million people (95% uncertainty interval [UI]=9.9-11.4 million) developed TB in 2022, compared with 10.3 million in 2021 and 10.0 million in 2020. TB caused an estimated 1.30 million deaths worldwide in 2022 (95% UI=1.18-1.43 million). This was […]
- 19 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 6 (4) , 320-327
Open AccessIsolation and Antibiotic Resistance Rates of Mycobacterium tuberculosis complex in Mycolor TK® System
Tuberculosis (TB) is a common disease with high mortality and morbidity worldwide. Globally, an estimated 10.6 million people (95% uncertainty interval [UI]=9.9-11.4 million) developed TB in 2022, compared with 10.3 million in 2021 and 10.0 million in 2020. TB caused an estimated 1.30 million deaths worldwide in 2022 (95% UI=1.18-1.43 million). This was […]
- 26 February 2024
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 36 (6) , 474-482
Antimicrobial dosing recommendations during continuous renal replacement therapy: different databases, different doses
Meticulous antimicrobial management is essential among critically ill patients with acute kidney injury, particularly if renal replacement therapy is needed. Many factors affect drug removal in patients undergoing continuous renal replacement therapy CRRT. In this study, we aimed to compare current databases that are frequently used to adjust CRRT dosages of antimicrobial drugs with the gold standard. The dosage recommendations from various databases for antimicrobial drugs eliminated by CRRT were investigated. The book 'Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys' was chosen as the gold standard. There were variations in the databases. Micromedex, UpToDate, and Sanford had similar rates to the gold standard of 45%, 35%, and 30%, respectively. The Micromedex database shows the most similar results to the gold standard source. In addition, a consensus was reached as a result of the expert panel meetings established to discuss the different antimicrobial dose recommendations of the databases.
- 26 February 2024
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 36 (6) , 474-482
Antimicrobial dosing recommendations during continuous renal replacement therapy: different databases, different doses
Meticulous antimicrobial management is essential among critically ill patients with acute kidney injury, particularly if renal replacement therapy is needed. Many factors affect drug removal in patients undergoing continuous renal replacement therapy CRRT. In this study, we aimed to compare current databases that are frequently used to adjust CRRT dosages of antimicrobial drugs with the gold standard. The dosage recommendations from various databases for antimicrobial drugs eliminated by CRRT were investigated. The book 'Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys' was chosen as the gold standard. There were variations in the databases. Micromedex, UpToDate, and Sanford had similar rates to the gold standard of 45%, 35%, and 30%, respectively. The Micromedex database shows the most similar results to the gold standard source. In addition, a consensus was reached as a result of the expert panel meetings established to discuss the different antimicrobial dose recommendations of the databases.
- Open Access
- 16 February 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 63 (5) , 107115
Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020–2022
- 16 February 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 63 (5) , 107115
Open AccessEnterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020–2022
- 1 January 2024
- Vol. 22 (1) , 153-159
An Emerging Issue: Carbapenem-Resistant Enterobacteriaceae in Solid-Organ Transplantation
Objectives: Bloodstream infections caused by carbapenem-resistant bacteria have increased globally. Solid-organ transplant recipients are more prone to these infections. This study aimed to compare the clinical courses of carbapenem-susceptible and carbapenem-resistant Enterobacteriaceae bloodstream infections and to identify risk factors for carbapenem resistance in solid- organ transplant recipients. Materials and Methods: For this retrospective descriptive study, data for solid-organ transplant recipients (age =18) treated from 2015 to 2022 were obtained from medical records. Enterobacteriaceaepositive blood culture was screened from laboratory data. Results: Among 72 patients, there were 100 bacteremia episodes. Patients included 40 kidney (55.6%), 21 liver (29.2%), 7 heart (9.7%), and 4 combined liver and kidney (5.6%) transplant recipients. Fifty-seven bacteremia episodes were recorded between 2015 and 2020, and 43 bacteremia episodes were recorded between 2020 and 2022. Carbapenem resistance was reported in 15.8% of patients before 2020, whereas this rate increased to 39.5% after 2020 (P =.007). Pitt bacteremia score =4 (P <.001), Charlson comorbidity index =4 (P =.021), chronic liver disease (P =.015), septic shock at admission (P =.001), hypotension at admission (P =.006), bacteremia episodes 48 hours after hospitalization (P =.004), hospitalization in the past 3 months (P =.004), and prior invasive procedure (P =.043) were significant factors for carbapenem resistance. Logistic regression analysis showed that bacteremia 48 hours after hospitalization (P =.002) and hospitalization in the past 3 months (P =.006) were independent risk factors. Conclusions: Carbapenem resistance increased significantly over the years. Bacteremia 48 hours after hospitalization and hospitalization within the past 3 months were determined to be risk factors for carbapenem resistance. Carbapenem-resistant infections are still nosocomial infections. Patients should be hospitalized for as a short time as possible, and both patients and their physicians should follow infection control and prevention methods.
- 1 January 2024
- Vol. 22 (1) , 153-159
An Emerging Issue: Carbapenem-Resistant Enterobacteriaceae in Solid-Organ Transplantation
Objectives: Bloodstream infections caused by carbapenem-resistant bacteria have increased globally. Solid-organ transplant recipients are more prone to these infections. This study aimed to compare the clinical courses of carbapenem-susceptible and carbapenem-resistant Enterobacteriaceae bloodstream infections and to identify risk factors for carbapenem resistance in solid- organ transplant recipients. Materials and Methods: For this retrospective descriptive study, data for solid-organ transplant recipients (age =18) treated from 2015 to 2022 were obtained from medical records. Enterobacteriaceaepositive blood culture was screened from laboratory data. Results: Among 72 patients, there were 100 bacteremia episodes. Patients included 40 kidney (55.6%), 21 liver (29.2%), 7 heart (9.7%), and 4 combined liver and kidney (5.6%) transplant recipients. Fifty-seven bacteremia episodes were recorded between 2015 and 2020, and 43 bacteremia episodes were recorded between 2020 and 2022. Carbapenem resistance was reported in 15.8% of patients before 2020, whereas this rate increased to 39.5% after 2020 (P =.007). Pitt bacteremia score =4 (P <.001), Charlson comorbidity index =4 (P =.021), chronic liver disease (P =.015), septic shock at admission (P =.001), hypotension at admission (P =.006), bacteremia episodes 48 hours after hospitalization (P =.004), hospitalization in the past 3 months (P =.004), and prior invasive procedure (P =.043) were significant factors for carbapenem resistance. Logistic regression analysis showed that bacteremia 48 hours after hospitalization (P =.002) and hospitalization in the past 3 months (P =.006) were independent risk factors. Conclusions: Carbapenem resistance increased significantly over the years. Bacteremia 48 hours after hospitalization and hospitalization within the past 3 months were determined to be risk factors for carbapenem resistance. Carbapenem-resistant infections are still nosocomial infections. Patients should be hospitalized for as a short time as possible, and both patients and their physicians should follow infection control and prevention methods.
- Open Access
- 1 May 2023
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 25 (1) , 63-69
COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS HOSPITALIZED DUE TO SARS-COV-2, INFLUENZA AND RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA
OBJECTIVE: Influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection are agents that spread through droplets, have similar symptoms and radiological findings, and can cause respiratory failure. This study was conducted to compare the clinical features and mortality rates of patients with novel coronavirus disease (COVID-19), influenza, and respiratory syncytial virus pneumonia. MATERIAL AND METHODS: A total of 182 patients who were hospitalized at Baskent University Medical Faculty Hospital due to COVID-19, influenza, and RSV were included in the study. Patients were grouped according to their clinical status. Demographic characteristics, comorbidities, laboratory and radiological findings, respiratory support treatments and mortality rates of the patients were recorded and compared between the groups. RESULTS: The mean age was 69.4±7 years in the COVID-19 group (n:115), 72.9±17.1 years in the influenza group (n:33), and 66.5±22.4 years in the RSV group (n:34). There was no difference in age between the groups (p=0.305). The hospitalization rate was higher for male patients in the COVID-19 group (p=0.036). There was no difference between the groups in terms of comorbidities (p>0.05). There was no difference in mortality rates between the COVID-19, RSV, and influenza patient groups (p=0.260). CONCLUSIONS: Viral infections with pulmonary involvement require special attention because they can have a poor clinical course. The severity of the clinical course of COVID-19 pneumonia, which causes deaths in the current century, is not different from the clinical course of viral infections such as influenza and RSV.
- 1 May 2023
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 25 (1) , 63-69
Open AccessCOMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS HOSPITALIZED DUE TO SARS-COV-2, INFLUENZA AND RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA
OBJECTIVE: Influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection are agents that spread through droplets, have similar symptoms and radiological findings, and can cause respiratory failure. This study was conducted to compare the clinical features and mortality rates of patients with novel coronavirus disease (COVID-19), influenza, and respiratory syncytial virus pneumonia. MATERIAL AND METHODS: A total of 182 patients who were hospitalized at Baskent University Medical Faculty Hospital due to COVID-19, influenza, and RSV were included in the study. Patients were grouped according to their clinical status. Demographic characteristics, comorbidities, laboratory and radiological findings, respiratory support treatments and mortality rates of the patients were recorded and compared between the groups. RESULTS: The mean age was 69.4±7 years in the COVID-19 group (n:115), 72.9±17.1 years in the influenza group (n:33), and 66.5±22.4 years in the RSV group (n:34). There was no difference in age between the groups (p=0.305). The hospitalization rate was higher for male patients in the COVID-19 group (p=0.036). There was no difference between the groups in terms of comorbidities (p>0.05). There was no difference in mortality rates between the COVID-19, RSV, and influenza patient groups (p=0.260). CONCLUSIONS: Viral infections with pulmonary involvement require special attention because they can have a poor clinical course. The severity of the clinical course of COVID-19 pneumonia, which causes deaths in the current century, is not different from the clinical course of viral infections such as influenza and RSV.